Haemonetics Co. (NYSE:HAE) Shares Acquired by Captrust Financial Advisors

Captrust Financial Advisors boosted its holdings in Haemonetics Co. (NYSE:HAE) by 30.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,248 shares of the medical instruments supplier’s stock after acquiring an additional 982 shares during the period. Captrust Financial Advisors’ holdings in Haemonetics were worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in HAE. Quarry LP purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $39,000. Daiwa Securities Group Inc. purchased a new position in Haemonetics during the second quarter worth $82,000. Canada Pension Plan Investment Board acquired a new position in shares of Haemonetics in the second quarter worth $83,000. Nisa Investment Advisors LLC lifted its position in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 632 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Haemonetics in the second quarter valued at $140,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $81.19 on Friday. The stock has a market capitalization of $4.08 billion, a P/E ratio of 34.15, a PEG ratio of 1.29 and a beta of 0.38. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The business’s fifty day moving average price is $80.99 and its 200 day moving average price is $81.64. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same quarter in the previous year, the business earned $0.99 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, research analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on HAE. Barrington Research restated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a report on Wednesday, December 4th. Citigroup reduced their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research note on Friday, November 8th. BTIG Research started coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Finally, Bank of America started coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.